"metastatic colorectal cancer" trang 11 - tải miễn phí từ tailieuXANH
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: A meta-analysis

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: A meta-analysis
11    40    1
The EPICURE study: A pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients

The EPICURE study: A pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients
9    36    1
A scoping review on the surgical management of metastatic bone disease of the extremities

A scoping review on the surgical management of metastatic bone disease of the extremities
10    47    1
CABOCOL-01 trial: A single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure

CABOCOL-01 trial: A single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
12    170    1
Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer
10    48    1
REMARRY and PURSUIT trials: Liquid biopsyguided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer

REMARRY and PURSUIT trials: Liquid biopsyguided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
6    226    1
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
11    50    1
A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
15    252    1
Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)

Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)
12    84    1
The DANTE trial protocol: A randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

The DANTE trial protocol: A randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
10    224    1
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: A retrospective comparative study

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: A retrospective comparative study
8    38    1
MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as firstline therapy for RAS and BRAF wildtype metastatic colorectal cancer: A study by the Australasian Gastrointestinal Trials Group (AGITG)

MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as firstline therapy for RAS and BRAF wildtype metastatic colorectal cancer: A study by the Australasian Gastrointestinal Trials Group (AGITG)
9    82    1
Labeling efficiency of Tb3+ conjugated CD133 monoclonal antibody nanocomplex targeting in vitro metastatic cancer cells

Labeling efficiency of Tb3+ conjugated CD133 monoclonal antibody nanocomplex targeting in vitro metastatic cancer cells
6    226    1
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
9    78    1
Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
8    56    1
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
8    75    1
Corticosteroid switch from prednisone to dexamethasone in metastatic castrationresistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

Corticosteroid switch from prednisone to dexamethasone in metastatic castrationresistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
9    73    1
Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: A case series

Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: A case series
10    114    1
A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
7    31    2
Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population

Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population
9    180    2
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.